Login to Your Account

Financings Roundup

Betting on Better Botox, Revance Pulls In $45M

By Tom Wall

Monday, June 13, 2011
Revance Therapeutics Inc. closed a $45 million debt financing and will use the proceeds to advance lead candidate RT001 botulinum toxin type A topical gel, currently in Phase II trials for lateral canthal lines (crow's feet wrinkles) and hyperhidrosis (excessive sweating), and a preclinical injectable botulinum toxin type A product RT002.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription